Rituximab-CHOP Consortium Program demonstrates high-risk gene expression signatures : a report from The activated B-cell subtype of diffuse large B-cell lymphoma and MYC / BCL 2 protein coexpression contributes to the inferior survival of

Chen, Ronald S. Go, Miguel A. Piris, Michael B. Møller, L. Jeffrey Medeiros and Ken H. Young J. M. Ferreri, Fan Zhou, Graham W. Slack, Randy D. Gascoyne, Meifeng Tu, Daina Variakojis, Weina Xiaoying Zhao, J. Han van Krieken, Qin Huang, Jooryung Huh, Weiyun Ai, Maurilio Ponzoni, Andrés April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W. L. Choi, Wei-min Liu, Carlo Visco, Yong Li, Roberto N. Miranda, Santiago Montes-Moreno, Karen Dybkaer, Shimin Hu, Zijun Y. Xu-Monette, Alexander Tzankov, Tina Green, Lin Wu, Aarthi Balasubramanyam, International DLBCL Rituximab-CHOP Consortium Program demonstrates high-risk gene expression signatures: a report from The activated B-cell subtype of diffuse large B-cell lymphoma and MYC/BCL2 protein coexpression contributes to the inferior survival of